Image de couverture de livre

Effect of body mass index and cholesterol‐rich apolipoprotein‐B‐containing lipoproteins on clinical outcome in NSCLC patients treated with immune checkpoint inhibitors‐based therapy: A retrospective analysis

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Zixin Hu, Yumin Zheng, Jiabin Zheng, Yan Wang, Jiangquan Liao, Zhening Liu, Jia Li, Huijuan Cui
Format:	Artículo Open Access
Publié:	Wiley 2024
Sujets:	Cancer Medicine
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Immune‐related adverse events in immune checkpoint inhibitor therapy for cancer
par: Katie Liao, et autres
Publié: (2025)

Inflammatory disease in people with multiple sclerosis treated with immune checkpoint inhibitors
par: Saira Afzal, et autres
Publié: (2024)

Body composition change indices combined with Prognostic Nutritional Index predicts the clinical outcomes of patients with gastric cancer treated with immune checkpoint inhibitor
par: Guiming Deng, et autres
Publié: (2024)

Persist or resist: Immune checkpoint inhibitors in EGFR‐mutated NSCLC
par: Pengcheng Zhu, et autres
Publié: (2024)

A case of coagulation factor V inhibitor induced by immune checkpoint inhibitor therapy
par: Yuki Haruta, et autres
Publié: (2024)

Delayed onset eruptive keratoacanthomas following immune checkpoint inhibitor therapy
par: Megan M. Tran, et autres
Publié: (2024)

Mechanism research of non‐coding RNA in immune checkpoint inhibitors therapy
par: Jie Bian, et autres
Publié: (2024)

Cardiovascular adverse events associated with immune checkpoint inhibitors: A retrospective multicenter cohort study
par: Yi Zheng, et autres
Publié: (2024)

Interpretable machine learning model predicting immune checkpoint inhibitor‐induced hypothyroidism: A retrospective cohort study
par: Su‐Yan Zhu, et autres
Publié: (2024)

Impact of immune‐related adverse events on survival outcomes in extensive‐stage small cell lung cancer patients treated with immune checkpoint inhibitors
par: Tadashi Nishimura, et autres
Publié: (2024)

Magnetic resonance imaging features of hypophysitis in patients with cancer treated with immune checkpoint inhibitors
par: Anna Angelousi, et autres
Publié: (2025)

Dupilumab for immune checkpoint inhibitors‐induced pruritic dermatoses: A retrospective, multicentric study
par: Damien Giacchero, et autres
Publié: (2025)

Efficacy of immune checkpoint inhibitor combination therapy prior to nephrectomy in advanced renal cell carcinoma: A retrospective pilot study
par: Sho Kiyota, et autres
Publié: (2024)

Clinical implications of PD ‐ L1 expression in oncogene‐driven NSCLC : Differential responses to targeted agents and immune checkpoint inhibitors
par: Xiaoxiao Fan, et autres
Publié: (2026)

A case of diverse psychiatric and functional impairments following immune checkpoint inhibitor therapy
par: Takako Ikegami, et autres
Publié: (2026)

Blood‐based biomarkers in soft tissue sarcoma: Implications for immune checkpoint inhibitor therapy
par: Brie‐Anne Mannah, et autres
Publié: (2025)

From clinical observations to molecular insights: Decoding immune checkpoint inhibitors‐induced prostatitis
par: Peng Luo, et autres
Publié: (2025)

Analysis of the clinical efficacy and safety of anti‐PD‐1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer
par: Shuling Shi, et autres
Publié: (2024)

Challenges and advances of immune checkpoint therapy
par: Lingyu Li, et autres
Publié: (2024)

Clinical relevance of immune checkpoint inhibitors for the analgesic effect of opioids: A retrospective propensity score analysis
par: Takahiro Sumimoto, et autres
Publié: (2024)

Early outcomes from a new multidisciplinary cardiometabolic clinic: real‐world experience in lowering low‐density lipoprotein cholesterol
par: Ying Yi Wendy Yap, et autres
Publié: (2026)

Effect of age on treatment outcomes of first‐line immune checkpoint inhibitor combination therapy for previously untreated advanced renal cell carcinoma
par: Hiroki Ishihara, et autres
Publié: (2025)

Role of gut microbiome in the outcome of lymphoma patients treated with checkpoint inhibitors—The MicroLinf Study
par: Beatrice Casadei, et autres
Publié: (2024)

Relationship of high‐density lipoprotein subfractions and apolipoprotein A‐I with fat in the pancreas
par: Yutong Liu, et autres
Publié: (2024)

The effect of common medications on the efficacy of immune checkpoint inhibitors
par: Daria Brinzevich, et autres
Publié: (2025)

Drug‐induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome
par: Marion Plaçais, et autres
Publié: (2024)

Notch signaling genes and CD8+ T‐cell dynamics: Their contribution to immune‐checkpoint inhibitor therapy in oral squamous cell carcinoma: A retrospective study
par: Kazuhiro Ogi, et autres
Publié: (2024)

What is the incidence and clinical significance of dry eye disease in patients treated with immune checkpoint inhibitors? A systematic review and meta‐analysis of ocular immune‐related adverse events
par: Kai‐Yang Chen, et autres
Publié: (2026)

Advances in cholesterol and lipoproteins detection for healthcare: A review
par: Jacopo Giaretta, et autres
Publié: (2026)

Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers
par: Kamal Al‐Eryani, et autres
Publié: (2024)

The association of osteoarthritis with de novo inflammatory arthritis in patients receiving immune checkpoint inhibitors: a retrospective study
par: Shiju Chen, et autres
Publié: (2026)

Immunometabolism: The role of gut‐derived microbial metabolites in optimising immune response during checkpoint inhibitor therapy
par: Agnieszka Beata Malczewski, et autres
Publié: (2025)

Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy
par: Soh Mee Park, et autres
Publié: (2024)

Correction to “The effect of common medications on the efficacy of immune checkpoint inhibitors”
Publié: (2026)

Prognostic biomarkers associated with immune checkpoint inhibitors in hepatocellular carcinoma
par: Xiu Chen, et autres
Publié: (2024)

Cytoreductive nephrectomy in the era of immune‐checkpoint inhibitors: back to the future?
par: Rocco Simone Flammia, et autres
Publié: (2026)

Revisiting the impact of common medications on immune checkpoint inhibitor efficacy
par: Parham Habibzadeh, et autres
Publié: (2026)

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas
par: Damien Sanogo, et autres
Publié: (2025)

Diagnostic guide for immune checkpoint inhibitor‐induced liver injury
par: Takanori Ito, et autres
Publié: (2024)

Efficacy and predictors of immune checkpoint inhibitors in patients with gallbladder cancer
par: Zhuo Cheng, et autres
Publié: (2024)